The month of September will herald the first fully in-person US Food and Drug Administration advisory committee meeting on a new drug application since the start of the COVID-19 pandemic in 2020.
The Antimicrobial Drugs Advisory Committee is scheduled to meet on 9 September on discuss Iterum Therapeutics plc’s NDA for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?